Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT -1.69% Return-on-Tangible-Equity is 5.51% as of Jun. 2026. The stock has 8 warning signs investors should review. Among 587 Healthcare Providers & Services companies, Resonance Health ranks better than 87.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Resonance Health's annualized net income for the quarter that ended in Jun. 2026 was A$0.09 Mil. Resonance Health's average shareholder tangible equity for the quarter that ended in Jun. 2026 was A$1.71 Mil. Therefore, Resonance Health's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 5.51%.
The historical rank and industry rank for Resonance Health's Return-on-Tangible-Equity or its related term are showing as below:
ASX:RHT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -377.15 Med: -3.24 Max: 176.55
Current: 139.19
During the past 13 years, Resonance Health's highest Return-on-Tangible-Equity was 176.55%. The lowest was -377.15%. And the median was -3.24%.
ASX:RHT's Return-on-Tangible-Equity is ranked better than 87.05% of 587
companies
in the Healthcare Providers & Services industry
Industry Median: 10.72
vs ASX:RHT: 139.19
Resonance Health (ASX:RHT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Resonance Health Return-on-Tangible-Equity Related Terms
Resonance Health Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Resonance Health's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Resonance Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Resonance Health's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.51% mean?
Resonance Health (ASX:RHT) has a Return-on-Tangible-Equity of 5.51% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #76 out of 587 companies in the Healthcare Providers & Services industry, placing it in the top 12.9%.
Is Resonance Health's Return-on-Tangible-Equity too high?
Resonance Health's current Return-on-Tangible-Equity is 5.51%. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.72. Resonance Health's value of 5.51% is 48.6% below this industry median. Based on the distribution chart, Resonance Health ranks #76 out of 587 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Resonance Health's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #76 out of 587 companies for Return-on-Tangible-Equity. This places Resonance Health in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.72. Resonance Health's value of 5.51% is 48.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.72, based on 587 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Return-on-Tangible-Equity of 5.51% is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Return-on-Tangible-Equity is 5.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.08, compared to a current price of A$0.06 — trading 27.5% below its estimated fair value. The current Return-on-Tangible-Equity is 5.51% and 48.6% below the Healthcare Providers & Services industry median of 10.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Return-on-Tangible-Equity is 5.51% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
